Welcome to our dedicated page for Inspiremd news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on Inspiremd stock.
InspireMD, Inc. (NSPR) is a medical device company whose news flow centers on its CGuard® Prime carotid stent system and proprietary MicroNet™ mesh technology for stroke prevention. Company press releases and SEC filings describe InspireMD as the developer of CGuard® Prime for the treatment of carotid artery stenosis, with a focus on making its products a standard approach in carotid stenting.
News about InspireMD often covers clinical milestones and peer-reviewed publications. For example, the company announced that results from its C-GUARDIANS pivotal trial of the CGuard® Prime carotid stent system were published in the Journal of the American College of Cardiology, with data showing low rates of disabling stroke or myocardial infarction through 30 days and low ipsilateral stroke rates through one year. InspireMD has also highlighted external clinical evidence such as the CREST-2 study in the New England Journal of Medicine, which it views as supportive of carotid artery stenting combined with medical therapy.
Investors following NSPR can also expect updates on regulatory and commercial developments. Recent filings report FDA PMA approval for the CGuard Prime Carotid Stent System in the United States and subsequent announcements of a U.S. commercial launch. Quarterly earnings releases describe the impact of CGuard Prime on revenue and provide commentary on procedure volumes and expansion of the company’s commercial team.
Additional news items include capital-raising transactions, such as private placements and warrant exercises, as well as changes in board composition and senior medical leadership. Together, these updates give readers insight into InspireMD’s clinical progress, regulatory status, commercialization efforts, and corporate governance. This page aggregates such NSPR news so readers can review the company’s key announcements in one place.
InspireMD (Nasdaq: NSPR) announced that its Compensation Committee approved inducement grants totaling 36,118 restricted shares to one new non-executive employee, granted under the company's 2024 Inducement Plan with a grant date of January 14, 2026.
The awards were made outside the 2021 Equity Incentive Plan as an inducement material to the employee entering employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock vests over three years: one-third on the first anniversary and the remaining two-thirds in equal installments on the second and third anniversaries, subject to continued employment on each vesting date.
InspireMD (Nasdaq: NSPR) announced publication of the C-GUARDIANS pivotal trial in JACC reporting low adverse event rates for the CGuard® Prime MicroNet™ carotid stent. The trial showed a 30-day disabling stroke or myocardial infarction (DSMI) rate of 0.95% and a 1-year ipsilateral stroke rate of 1.93% in a cohort that included 25% symptomatic patients. No unexpected device-related adverse events were reported. InspireMD highlighted that results compare favorably with prior carotid stenting pivotal studies and said the device is FDA PMA-approved for treatment of carotid artery stenosis in the U.S.
InspireMD (Nasdaq: NSPR) welcomed publication of the CREST-2 trial in the New England Journal of Medicine on Nov 24, 2025, and presentation at SVIN and VEITH on Nov 21, 2025. CREST-2 found that adding carotid artery stenting (CAS) to medical therapy in patients with high-grade asymptomatic carotid stenosis significantly reduced the composite risk of perioperative stroke or death or ipsilateral stroke through 4 years versus intensive medical therapy alone.
The trial reported that carotid endarterectomy (CEA) did not provide a significant benefit vs medical therapy in a separate arm. InspireMD highlighted its CGuard platform, citing a 1.93% major adverse event rate through 12 months in its C-GUARDIANS trial and >b>65,000 global implants as supporting evidence.
InspireMD (Nasdaq: NSPR) announced inducement grants approved November 20, 2025, awarding a total of 122,054 restricted shares to eight new non-executive employees under the company’s 2024 Inducement Plan.
The grants were made outside the 2021 Equity Incentive Plan as permitted by Nasdaq Listing Rule 5635(c)(4) and vest over three years: one-third on the first anniversary and two equal installments on the second and third anniversaries, subject to continued employment.
InspireMD (Nasdaq: NSPR) will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:30 PM ET. The company, developer of the CGuard Prime carotid stent system, said a live audio webcast and a replay will be available on its Investor Calendar page. Investors can access the event via the provided webcast link and listen live or via the replay on the company website.
InspireMD (Nasdaq: NSPR) reported third quarter 2025 results and operational milestones on November 4, 2025. Total revenue rose 39% to $2.5M versus prior year, with U.S. revenue $497,000 and international $2.0M. The company initiated the U.S. commercial launch of CGuard Prime, recording over 100 U.S. procedures in leading hospitals. Gross profit was $864,000. Operating expenses increased to $13.9M (up 57%) driven by U.S. commercial hires and U.S. headquarters costs. Net loss was $12.7M, $0.17 per share versus $7.9M, $0.16 a year earlier. Cash and marketable securities totaled $63.4M, supported by $58M in gross proceeds raised in July. Management hosted a conference call on November 4, 2025 to discuss results.
InspireMD (Nasdaq: NSPR) appointed Peter A. Soukas, M.D. as Chief Medical Officer effective Nov 3, 2025 to advance clinical and medical strategy around its CGuard Prime carotid stent system.
Dr. Soukas will help support the planned U.S. launch, maintain his clinical practice, and bring academic and trial experience as Director of Vascular Medicine at The Miriam Hospital and Associate Professor at Brown University.
InspireMD (Nasdaq: NSPR) announced it will release its third quarter 2025 financial results on Tuesday, November 4, 2025.
The company will host a conference call and webcast on November 4, 2025 at 8:30 a.m. Eastern Time to review results and recent highlights. Domestic callers may dial 1-800-579-2543; international callers may dial 1-785-424-1789. Investors can join the live webinar via InspireMD’s website or the provided webcast registration link. A replay will be available shortly after the call and archived on the company website.
InspireMD (Nasdaq: NSPR) announced that its Compensation Committee approved inducement grants of 40,513 restricted shares to three new non-executive employees, granted outside the 2021 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4).
The grants were made under InspireMD's 2024 Inducement Plan with a grant date of October 7, 2025. The restricted stock vests over three years: one-third on the first anniversary and the remainder in two equal installments on the second and third anniversaries, subject to continued employment.
InspireMD (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system, has announced the approval of inducement grants for five new non-executive employees. The Compensation Committee approved a total of 88,324 shares of restricted stock under the company's 2024 Inducement Plan.
The grants, made outside the company's 2021 Equity Incentive Plan, have a grant date of September 24, 2025. The restricted stock follows a three-year vesting schedule, with one-third vesting on the first anniversary and the remaining portions vesting equally on the second and third anniversaries, contingent on continued employment.
FAQ
What is the current stock price of Inspiremd (NSPR)?
What is the market cap of Inspiremd (NSPR)?
